Edwards Lifesciences announced new data at New York Valves 2026 reinforcing its leadership in structural heart innovation. The PROGRESS trial baseline characteristics showed over 95% of moderate aortic stenosis patients were symptomatic and more than 70% had two or more at-risk features, with a mean age of 78 years. Seven-year durability data from the PARTNER 3 trial and findings from the EARLY TAVR trial further supported the SAPIEN 3 platform's long-term performance. Additionally, data from over 4,500 patients in the STS/ACC TVT Registry highlighted the PASCAL system's safety and effectiveness for mitral regurgitation, while one-year ENCIRCLE trial MAC Registry results supported SAPIEN M3 in patients with mitral annular calcification.
Edwards Lifesciences CorpNew clinical data reinforces leadership in structural heart innovation, supporting long-term performance of SAPIEN 3 and PASCAL systems.